Hematopoietic cancers accounted for 23.9% of cases in patients with LIG4 deficiency, particularly lymphomas (both EBV-positive and EBV-negative), lymphoid leukemias, and MDS. This evidence concerns the gene LIG4 and lymphoid leukemia.